Horizon Technology Finance Corporation is a business development company specializing in lending and and investing in development-stage investments. It focuses on making secured debt and venture lending investments to venture capital backed companies in the technology, life science, healthcare information and services, and cleantech industries. It seeks to invest in companies in the United States.
IPO Year: 2010
Exchange: NASDAQ
Website: horizontechfinance.com
Date | Price Target | Rating | Analyst |
---|---|---|---|
12/17/2024 | $8.25 | Sell → Neutral | Compass Point |
2/28/2024 | Buy → Neutral | Ladenburg Thalmann | |
1/8/2024 | $11.00 | Neutral → Sell | B. Riley Securities |
10/17/2023 | $10.00 | Neutral → Sell | Compass Point |
9/27/2023 | $11.00 → $10.50 | Sell → Neutral | Compass Point |
8/4/2023 | $11.00 | Neutral → Sell | Compass Point |
4/11/2023 | $12.50 | Buy | Ladenburg Thalmann |
12/20/2022 | $11.50 → $10.50 | Mkt Perform → Underperform | Keefe Bruyette |
10/5/2022 | $10.00 | Neutral | Janney |
9/16/2022 | $10.50 | Neutral | B. Riley Securities |
8-K - Horizon Technology Finance Corp (0001487428) (Filer)
DEFA14A - Horizon Technology Finance Corp (0001487428) (Filer)
DEFA14A - Horizon Technology Finance Corp (0001487428) (Filer)
DEF 14A - Horizon Technology Finance Corp (0001487428) (Filer)
PRE 14A - Horizon Technology Finance Corp (0001487428) (Filer)
10-Q - Horizon Technology Finance Corp (0001487428) (Filer)
8-K - Horizon Technology Finance Corp (0001487428) (Filer)
8-K - Horizon Technology Finance Corp (0001487428) (Filer)
8-K/A - Horizon Technology Finance Corp (0001487428) (Filer)
8-K - Horizon Technology Finance Corp (0001487428) (Filer)
Vesta Healthcare, a virtual care provider group for people with home care, today announced the close of $65 million in a Series C round with new debt financing. The equity round was led by Boston-based RA Capital Management, with participation from Oak HC/FT, Chrysalis Ventures, CareCentrix/Walgreens, Nationwide, Kaiser Permanente Ventures, Lux Capital, Generator Ventures, Deerfield Management and others. Debt financing was provided by Horizon Technology Finance Corporation, an affiliate of Monroe Capital. "The home is the last frontier of healthcare, and caregivers are the most vital yet disconnected resource in the delivery system," said Randy Klein, CEO of Vesta Healthcare. "We're pr
FARMINGTON, Conn., June 9, 2021 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("Horizon," or the "Company"), a leading specialty finance company that provides capital in the form of secured loans to venture capital backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced that it has appointed Daniel S. Devorsetz as Chief Operating Officer effective immediately. In addition, Devorsetz has concurrently been appointed as Chief Operating Officer of Horizon's external investment advisor, Horizon Technology Finance Management LLC (the "Advisor" or "HTFM"). He currently serves as Chief Investment Of
- HRZN Originates $59.1 Million of New Loans in Q4 - - HRZN Ends Year with Committed Backlog of $206.5 Million - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN" or "Horizon"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the fourth quarter ended December 31, 2024 and an update on the lending platform ("Horizon Platform") of Horizon Technology Finance Management LLC ("HTFM"), its investment adviser. "We had a strong close to
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to Onkos Surgical ("Onkos"), of which $30 million has been initially funded. Onkos intends to use the proceeds of the loan facility to accelerate manufacturing and commercialization of NanoCept™, a groundbreaking, antibacterial coating technology that is used on FDA-granted orthopaedic
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $10 million venture loan facility to OneNetwork, Inc. dba Finexio, of which $5 million has been initially funded. Finexio, a leader in the B2B payments industry, delivers "Accounts Payable (AP) Payments as a Service", a fully-managed AP payments solution that leverages AI to optimize, monetize, and secure the entire pa
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $10 million venture loan facility to Ursa Space Systems Inc. ("Ursa Space"). Ursa Space is a leading satellite intelligence company serving government and commercial clients worldwide, providing all-weather monitoring, analytics and imagery via an extensive virtual network of over 200 satellites. Its proprietary technol
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that its board of directors has declared monthly cash distributions of $0.11 per share, payable in each of January, February and March 2025. The following tables show these distributions, payable as set forth in the tables below, total $0.33 per share. Since its 2010 initial public offering, Horizon has paid a total of $286 million in dist
- Third Quarter 2024 Net Investment Income per Share of $0.32; NAV per Share of $9.06 - - Debt Portfolio Yield of 15.9% - - HRZN Ends Quarter with Committed Backlog of $190 Million - - Declares Regular Monthly Distributions Totaling $0.33 per Share through March 2025 - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the third quarter ended September 30, 20
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that it plans to release financial results for the third quarter ended September 30, 2024 on Tuesday, October 29, 2024, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, October 30, 2024, at 9:00 a.m. ET. The conference call will feature remarks by Robert D. Pomeroy, Jr., C
- HRZN Originates $93.1 Million of New Loans in Q3 - - HRZN Ends Quarter with Committed Backlog of $189.9 Million - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("HRZN" or "Horizon"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today provided its portfolio update for the third quarter ended September 30, 2024 and an update on the lending platform ("Horizon Platform") of Horizon Technology Finance Management LLC ("HTFM"), its investment adviser. "We made excellent prog
TEMPE, Ariz., Sept. 12, 2024 /PRNewswire/ -- GT Medical Technologies, Inc. ("GT MedTech" or the "Company"), a medical device company with a corporate purpose of improving the lives of patients with brain tumors, today announced it has secured a $35 million venture loan facility, of which $15 million has been initially funded from Horizon Technology Finance Corporation (NASDAQ:HRZN), an affiliate of Monroe Capital. The Company will use the loan proceeds to execute strategic commercial and clinical expansion plans for GammaTile®. These initiatives will drive key corporate object
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced it has provided a $35 million venture loan facility to GT Medical Technologies, Inc. ("GT MedTech"), of which $15 million has been initially funded. GT MedTech, through its innovative flagship product, GammaTile®, offers a proprietary solution to treat brain tumors. GammaTile is a bioresorbable collagen tile embedded with radiation seeds
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
- Third Quarter 2024 Net Investment Income per Share of $0.32; NAV per Share of $9.06 - - Debt Portfolio Yield of 15.9% - - HRZN Ends Quarter with Committed Backlog of $190 Million - - Declares Regular Monthly Distributions Totaling $0.33 per Share through March 2025 - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the third quarter ended September 30, 20
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that it plans to release financial results for the third quarter ended September 30, 2024 on Tuesday, October 29, 2024, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, October 30, 2024, at 9:00 a.m. ET. The conference call will feature remarks by Robert D. Pomeroy, Jr., C
- Second Quarter 2024 Net Investment Income per Share of $0.36; NAV per Share of $9.12 - - Debt Portfolio Yield of 15.9% - - HRZN Ends Quarter with Committed Backlog of $138 Million - - Declares Regular Monthly Distributions Totaling $0.33 per Share through December 2024 - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the second quarter ended June 30
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that it plans to release financial results for the second quarter ended June 30, 2024 on Tuesday, July 30, 2024, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, July 31, 2024, at 9:00 a.m. ET. The conference call will feature remarks by Robert D. Pomeroy, Jr., Chairman a
- First Quarter 2024 Net Investment Income per Share of $0.38; NAV per Share of $9.64 - - Debt Portfolio Yield of 15.6% - - HRZN Ends Quarter with Committed Backlog of $168 Million - - Declares Regular Monthly Distributions Totaling $0.33 per Share through September 2024 - Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, today announced its financial results for the first quarter ended March 31
Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that it plans to release financial results for the first quarter ended March 31, 2024 on Tuesday, April 30, 2024, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, May 1, 2024, at 9:00 a.m. ET. The conference call will feature remarks by Robert D. Pomeroy, Jr., Chairman an
- Fourth Quarter 2023 Net Investment Income per Share of $0.45; NAV per Share of $9.71 - - Annual Debt Portfolio Yield of 16.6% - - HRZN Ends Year with Committed Backlog of $218 Million - - Declares Regular Monthly Distributions Totaling $0.33 per Share through June 2024 and $0.05 Special Distribution Payable in April 2024 - FARMINGTON, Conn., Feb. 27, 2024 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon" or the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustaina
VANCOUVER, BC, Feb. 21, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") is pleased to announce has completed the acquisition of the entire portfolio of discovery, preclinical and clinical development stage assets of former Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV"). On February 11th, 2024, the Company executed the definitive Asset Purchase Agreement for the extensive technology portfolio from HIMV, LLC, an acquisition vehicle formed by Horizon Technology Finance Corporation (NASDAQ:HRZN) and IMV's other secured creditors for the purpose of acquiring IMV's intellectual property t
FARMINGTON, Conn., Feb. 13, 2024 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ:HRZN) ("Horizon") (the "Company"), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services, and sustainability industries, announced today that it plans to release financial results for the fourth quarter ended December 31, 2023 on Tuesday, February 27, 2024, after the close of market trading. The Company has scheduled a conference call to discuss the results on Wednesday, February 28, 2024, at 9:00 a.m. ET. The conferen
VANCOUVER, BC, Feb. 12, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE:BIOV) (FRA: 5LB) (OTCQB:BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement dated February 11th, 2024 to acquire the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX™ immune educating platform technology, developed by Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA ("IMV"). BioVaxys acquired the extensive technology portfolio from HIMV, LLC, an acquisition vehicle formed by Horizon Technolo
Compass Point upgraded Horizon Technology Finance from Sell to Neutral and set a new price target of $8.25
Ladenburg Thalmann downgraded Horizon Technology Finance from Buy to Neutral
B. Riley Securities downgraded Horizon Technology Finance from Neutral to Sell and set a new price target of $11.00
Compass Point downgraded Horizon Technology Finance from Neutral to Sell and set a new price target of $10.00
Compass Point upgraded Horizon Technology Finance from Sell to Neutral and set a new price target of $10.50 from $11.00 previously
Compass Point downgraded Horizon Technology Finance from Neutral to Sell and set a new price target of $11.00
Ladenburg Thalmann initiated coverage of Horizon Technology Finance with a rating of Buy and set a new price target of $12.50
Keefe Bruyette downgraded Horizon Technology Finance from Mkt Perform to Underperform and set a new price target of $10.50 from $11.50 previously
Janney initiated coverage of Horizon Technology Finance with a rating of Neutral and set a new price target of $10.00
B. Riley Securities resumed coverage of Horizon Technology Finance with a rating of Neutral and set a new price target of $10.50
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
4 - Horizon Technology Finance Corp (0001487428) (Issuer)
3 - Horizon Technology Finance Corp (0001487428) (Issuer)
3 - Horizon Technology Finance Corp (0001487428) (Issuer)
3 - Horizon Technology Finance Corp (0001487428) (Issuer)
3 - Horizon Technology Finance Corp (0001487428) (Issuer)